New Delhi, Sept. 18 -- The Union health ministry on Thursday said it has issued an advisory for states to ensure that stem cell therapy is offered as standard clinical care only for approved disease conditions. Also, its use for autism still remains restricted to clinical trials approved by the authorities concerned. ".the advisory has been issued in view of the judgment dated 30 January 2026 of the Hon'ble Supreme Court in Yash Charitable Trust & Ors. v. Union of India & Ors., W.P. (C) No. 369 of 2022. The advisory reiterates the existing framework governing stem cell research and therapy and seeks to ensure that stem cell therapy is permitted as standard care in routine clinical practice only for disease conditions/indications included in the list approved by the Ministry of Health and Family Welfare," read the health ministry statement. For Autism Spectrum Disorder (ASD), the advisory stipulates that the therapeutic use of any type of stem cell in autism must remain restricted to duly approved clinical trials, in accordance with the National Guidelines for Stem Cell Research, 2017, issued jointly by the ICMR and Department of Biotechnology, and other applicable government instructions issued from time to time. htc...